| Literature DB >> 32656871 |
Mao Zhou1, You Lan1, Siyi Wang1, Qingxia Liu1, Zijuan Jian1, Yanming Li1, Xia Chen1, Qun Yan1, Wenen Liu1.
Abstract
BACKGROUND: The type VI secretion system (T6SS) has been identified as a novel virulence factor. This study aimed to investigate the prevalence of the T6SS genes in Klebsiella pneumoniae-induced bloodstream infections (BSIs). We also evaluated clinical and molecular characteristics of T6SS-positive K pneumoniae.Entities:
Keywords: zzm321990Klebsiella pneumoniaezzm321990; T6SS; bloodstream infections; hypervirulent; virulence factor
Year: 2020 PMID: 32656871 PMCID: PMC7676210 DOI: 10.1002/jcla.23459
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Primers used in this study
| Primer name | DNA sequence (5′‐3′) | Amplicon size (bp) | |
| Capsular serotypes | |||
| K1 | F: GGTGCTCTTTACATCATTGC | 1283 | |
| R: GCAATGGCCATTTGCGTTAG | |||
| K2 | F: GACCCGATATTCATACTTGACAGAG | 641 | |
| R: CCTGAAGTAAAATCGTAAATAGATGGC | |||
| K5 | F: TGGTAGTGATGCTCGCGA | 741 | |
| R: CCTGAACCCACCCCAATC | |||
| K20 | F: CGGTGCTACAGTGCATCATT | 280 | |
| R: GTTATACGATGCTCAGTCGC | |||
| K54 | F: CATTAGCTCAGTGGTTGGCT | 881 | |
| R: GCTTGACAAACACCATAGCAG | |||
| K57 | F: CTCAGGGCTAGAAGTGTCAT | 1037 | |
| R: CACTAACCCAGAAAGTCGAG | |||
| Virulence genes | |||
|
| F: CATAAGAGTATTGGTTGACAG | 461 | |
| R: CTTGCATGAGCCATCTTTCA | |||
|
| F: GGTTGGKTCAGCAATCGTA | 169 | |
| R: ACTATTCCGCCAACTTTTGC | |||
|
| F: CATTACGCACCTTTGTCAGC | 764 | |
| R: GAATGTGTCGGCGATCAGCTT | |||
|
|
F: GGGAAAGGCTTCTCTGCCAT R: TTATTCGCCACCACGCTCTT | 920 | |
|
|
F: GCATAGGCGGATACGAACAT R: CACAGGGCAATTGCTTACCT | 556 | |
|
|
F: AAGCTATCGCTGTACTTCCGGCA R: GGCGTTGGCGCTCAGATAGG | 340 | |
|
|
F: GGCCTTTGTCCAGAGCTACG R: GGGTCTGGCGCAGAGTATGC | 638 | |
|
|
F: GACGGAAACAGCACGGTAAA R: GAGCATAATAAGGCGAAAGA | 242 | |
|
|
F: GCATAGGCGGATACGAACAT R: CACAGGGCAATTGCTTACCT | 556 | |
|
|
F: TGTGTGCTGTGGGTGAAAGC R: ATGTTCGGTGAGATTCGCCAGT | 2711 | |
|
|
F: GTCAACTGGGCCTTTGAGCCGTC R: TATGGGCGTAAACGCCGGTGAT | 400 | |
| T6SS genes | |||
|
| F: TCCCGACCGATAACAACACC | 242 | |
| R: GATGTCGTGCATCAGGGGAT | |||
|
| F: TGAGCGTGTTTGTGCGAAAG | 259 | |
| R: TGACGCCCGTAATATCCTGC | |||
|
| F: GACCGCTTACGGACAACTGA | 485 | |
| R: CACTCAGCACCCAGTCCATT | |||
Capsular types and virulence gene distribution of T6SS‐positive and T6SS‐negative K. pneumoniae bloodstream isolates
| Virulence factors | All (n = 344) (%) | T6SS‐positive (n = 69) (%) | T6SS‐negative (n = 275) (%) |
|
|---|---|---|---|---|
| Virulence gene | ||||
|
| 79(23.0) | 30(43.5) | 49(17.8) | .000 |
|
| 39(11.3) | 24(34.8) | 15(5.5) | .000 |
|
| 192(55.8) | 45(65.2) | 147(53.5) | .079 |
|
| 99(28.8) | 22(31.9) | 77(28.0) | .524 |
|
| 86(25.0) | 30(43.5) | 56(20.4) | .000 |
|
| 326(94.8) | 67(97.1) | 259(94.2) | .330 |
|
| 86(25.0) | 28(40.6) | 58(21.1) | .001 |
|
| 192(55.8) | 34(49.3) | 158(57.5) | .221 |
|
| 175(50.9) | 44(63.8) | 131(47.6) | .017 |
|
| 45(13.1) | 20(29.0) | 25(9.1) | .000 |
|
| 336(97.7) | 69(100.0) | 267(97.1) | .366 |
| Capsular serotype | ||||
| K1 | 38(11.0) | 17(24.6) | 21(7.6) | .000 |
| K2 | 36(10.5) | 5(7.2) | 31(11.3) | .329 |
| K5 | 4(1.2) | 1(1.4) | 3(1.1) | .804 |
| K54 | 3(0.9) | 0(0.0) | 3(1.1) | 1.000 |
| K20 | 3(0.9) | 0(0.0) | 3(1.1) | 1.000 |
| K57 | 18(5.2) | 5(7.2) | 13(4.7) | .401 |
| HVKP | 27(7.8) | 14(20.3) | 13(4.7) | .000 |
Abbreviations: HVKP, hypervirulent Klebsiella pneumoniae.
A P value < .05 was considered to be statistically significant.
MLST of T6SS‐positive and T6SS‐negative K. pneumoniae bloodstream isolates
| Sequence types | All (n = 27) | T6SS‐positive (n = 14) | T6SS‐negative (n = 13) |
|
|---|---|---|---|---|
| ST23 | 13(48.1%) | 11(78.6%) | 2(15.4%) | .002 |
| ST268 | 3(11.1%) | 0 | 3(23.1%) | .098 |
| ST25 | 2(7.4%) | 0 | 2(15.4%) | .222 |
| ST375 | 2(7.4%) | 1(7.1%) | 1(7.7%) | 1.000 |
| ST218/ST39/ST2446/ST893/ ST65 | 1(3.7%) | 0 | 1(7.7%) | .481 |
| ST1534/ST412 | 1(3.7%) | 1(7.1%) | 0 | 1.000 |
A P value < .05 was considered to be statistically significant.
Antimicrobial resistance of T6SS‐positive and T6SS‐negative K pneumoniae bloodstream isolates
| Antimicrobial agent | All (n = 344) (%) | T6SS‐positive (n = 69) (%) | T6SS‐negative (n = 275) (%) |
|
|---|---|---|---|---|
| Cefoperazone‐sulbactam | 114(33.1) | 15(21.7) | 99(36.0) | .024 |
| Ampicillin‐sulbactam | 199(57.8) | 32(46.4) | 167(60.7) | .031 |
| Piperacillin‐tazobactam | 109(31.7) | 16(23.2) | 93(33.8) | .090 |
| Cefazolin | 192(55.8) | 28(40.6) | 164(59.6) | .004 |
| Ceftazidime | 134(39.0) | 22(31.9) | 112(40.7) | .178 |
| Ceftriaxone | 173(50.3) | 26(37.7) | 147(53.5) | .019 |
| Cefepime | 132(38.4) | 20(29.0) | 112(40.7) | .073 |
| Cefotan | 112(32.6) | 15(21.7) | 97(35.3) | .032 |
| Aztreonam | 163(47.4) | 23(33.3) | 140(50.9) | .009 |
| Ertapenem | 110(32.0) | 15(21.7) | 95(34.5) | .041 |
| Meropenem | 102(29.7) | 14(20.3) | 88(32.0) | .057 |
| Imipenem | 100(29.1) | 14(20.3) | 86(31.3) | .072 |
| Tobramycin | 72(20.9) | 9(13.0) | 63(22.9) | .072 |
| Amikacin | 60(17.4) | 5(7.2) | 55(20.0) | .013 |
| Gentamicin | 108(31.4) | 10(14.5) | 98(35.6) | .001 |
| Levofloxacin | 118(34.3) | 16(23.2) | 102(37.1) | .030 |
| Ciprofloxacin | 125(36.3) | 17(24.6) | 108(39.3) | .024 |
| Trimethoprim‐sulfamethoxazole | 143(41.6) | 24(34.8) | 119(43.3) | .201 |
| Furantoin | 162(47.1) | 27(39.1) | 135(49.1) | .138 |
| Tigecycline | 5(1.5) | 1(1.4) | 4(1.5) | 1.000 |
| CR‐KP | 110(32.0) | 15(21.7) | 95(34.5) | .041 |
| ESBL+ | 48(14.0) | 6(8.7) | 42(15.3) | .159 |
Abbreviations: CR‐KP, carbapenem‐resistant Klebsiella pneumoniae;ESBL+, producing extended‐spectrum beta‐lactamase.
A P value < .05 was considered to be statistically significant.
Clinical characteristics of T6SS‐positive and T6SS‐negative K pneumoniae bloodstream isolates
| Characteristics | All (n = 344) | T6SS‐positive (n = 69) | T6SS‐negative (n = 275) |
|
|---|---|---|---|---|
| Age | 42.69 ± 25.83 | 41.96 ± 24.76 | 42.86 ± 26.13 | .684 |
| Gender | ||||
| Male | 210(61.0%) | 45(65.2%) | 165(60.0%) | .427 |
| Female | 134(39.0%) | 24(34.8%) | 110(40.0%) | |
| Acquisition | ||||
| Community‐acquired | 192(55.8%) | 46(66.7%) | 146(53.1%) | .042 |
| Hospital‐acquired | 152(44.2%) | 23(33.3%) | 129(46.9%) | |
| Primary site | ||||
| Respiratory tract | 212(61.6%) | 42(60.9%) | 170(61.8%) | .885 |
| Biliary tract | 15(4.4%) | 1(1.4%) | 14(5.1%) | .321 |
| Intra‐abdomen | 38(11.0%) | 5(7.2%) | 33(12.0%) | .260 |
| Liver abscess | 10(2.9%) | 5(7.2%) | 5(1.8%) | .016 |
| Brain | 13(3.8%) | 4(5.8%) | 9(3.3%) | .326 |
| Urinary tract | 12(3.5%) | 3(4.3%) | 9(3.3%) | .663 |
| Others | 44(12.8%) | 9(13.0%) | 35(12.7%) | .944 |
| Personal history | ||||
| Smoking history | 69(20.1%) | 12(17.4%) | 57(20.7%) | .536 |
| Drinking history | 63(18.3%) | 10(14.5%) | 53(19.3%) | .359 |
| Chemotherapy history | 58(16.9%) | 12(17.4%) | 46(16.7%) | .895 |
| Blood transfusion history | 26(7.6%) | 3(4.3%) | 23(8.4%) | .318 |
| Underlying condition | ||||
| Hypertension | 83(24.1%) | 17(24.6%) | 66(24.0%) | .912 |
| Cancer | 59(17.2%) | 12(17.4%) | 47(17.1%) | .953 |
| Diabetes mellitus | 55(16.0%) | 14(20.3%) | 41(14.9%) | .276 |
| Premature baby | 44(12.8%) | 12(17.4%) | 32(11.6%) | .201 |
| Hematological diseases | 41(11.9%) | 7(10.1%) | 34(12.4%) | .611 |
| Biliary tract disease | 36(10.5%) | 11(15.9%) | 25(9.1%) | .096 |
| Pulmonary infection | 33(9.6%) | 6(8.7%) | 27(9.8%) | .777 |
| Acute severe pancreatitis | 28(8.1%) | 6(8.7%) | 22(8.0%) | .850 |
| Liver cirrhosis | 13(3.8%) | 3(4.3%) | 10(3.6%) | .729 |
| Multiple bacterial infections | 66(19.2%) | 11(15.9%) | 55(20.0%) | .444 |
| Septic shock | 85(24.7%) | 13(18.8%) | 72(26.2%) | .206 |
| Death in hospital | 19(5.5%) | 6(8.7%) | 13(4.7%) | .197 |
A P value < .05 was considered to be statistically significant.